LOS ANGELES, CA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced that co-founder of eXoZymes, Tyler Korman, PhD, has taken on the role of Chief Scientific Officer, while Amy Lunzer - an accomplished business, supply-chain, and operations executive - is appointed as Chief of Staff.
CSO of eXoZymes, Tyler Korman, PhD, states, "I'm excited to announce that I'm now the Chief Scientific Officer of eXoZymes! This journey started over 20 years ago including founding Invizyne, which then became eXoZymes. I'm grateful to have held roles as Director of R&D to VP of Research and now CSO - where I can really push through our strategy for how we become the leader in biomanufacturing. As a team, I'm proud of the developments that we've pioneered - by providing access to new molecules, we are opening the door to potential treatments for a variety of diseases and providing solutions for longevity, metabolic health, and overall wellness."
Korman, adds: "In my opinion, we stand at a crossroads where we need new solutions to be able to produce important molecules for use as nutraceuticals and pharmaceuticals - and I think we have those solutions. That makes me excited about the future of biomanufacturing!"
Click here for a full video interview with CSO, Tyler Korman.
Michael Heltzen, CEO of eXoZymes, adds, "Dr. Korman has continually demonstrated his grasp of both being a visionary - helping to push our technology and the biomanufacturing field forward - while also engaging in dialogs with potential partners to create biosolutions that make products that have been very hard to make or never existed before. Additionally, both Amy Lunzer and Tyler Korman embody the exceptional kind of talent, experience, values, and breadth of capabilities we're bringing together to advance our company and the future of biomanufacturing!"
These changes are taking effect immediately and will also be covered in today's 2025 Q3 update call, which starts at 5PM EST.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce very valuable natural products, via a commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more on exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes
SOURCE: eXoZymes
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/exozymes-announces-cell-free-biomanufacturing-pioneer-tyler-korman-as-cso-and-amy-lun-1102250